WCG
GILD icon

Weaver Consulting Group’s Gilead Sciences GILD Stock Holding History

Weaver Consulting Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,120
Closed -$71K – 427
2020
Q3 		$71K Sell
1,120
-160
-13% -$11.1K 0.04% 221
2020
Q2 		$99K Buy
1,280
+55
+4% +$4.21K 0.06% 189
2020
Q1 		$92K Buy
1,225
+706
+136% +$48.8K 0.06% 169
2019
Q4 		$33K Hold
519
– – 0.02% 291
2019
Q3 		$35K Hold
519
– – 0.02% 265
2019
Q2 		$35K Hold
519
– – 0.02% 256
2019
Q1 		$34K Buy
+519
New +$34.5K 0.01% 570

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Weaver Consulting Group's GILD Position: Q4 2020 in Review

Weaver Consulting Group sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 1,120 shares — an estimated $71K sold.

Weaver Consulting Group first reported a position in GILD in Q1 2019 and held it in 7 quarters. The position peaked at $99K in Q2 2020. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

  • Weaver Consulting Group reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 1,120 Gilead Sciences shares in Q4 2020, an estimated $71K.
  • Weaver Consulting Group first reported a position in Gilead Sciences in Q1 2019 and held it in 7 quarters.
  • Weaver Consulting Group's Gilead Sciences position peaked at $99K in Q2 2020.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.